Oncocyte (IMDX) Stock Price, News & Analysis

Company Overview

Oncocyte Corporation is a molecular diagnostics company focused on developing and commercializing tests intended to support cancer treatment decisions. Its technologies use genomic and other molecular information to help physicians assess disease characteristics, recurrence risk, and potential response to therapy.

The company’s historical product portfolio has included DetermaRx, a genomic test designed to identify patients with early-stage lung cancer who may face a higher risk of recurrence after surgery, and DetermaIO, which was developed to help evaluate the tumor immune environment and potential response to immunotherapy. Oncocyte has also pursued tests for evaluating the likelihood that lung nodules are malignant.

Oncocyte was founded in 2009 and has focused primarily on oncology applications in the United States, working with physicians, laboratories, and health care providers. The company has undergone strategic and corporate changes over time, including transactions involving its diagnostic assets. Publicly available information about its current leadership and operations under the NASDAQ symbol IMDX is limited.

Key Stats

• Today's Range: $3.36 to $3.60
• 50-Day Range: $3.18 to $5.12
• 52-Week Range: $2.42 to $8.51
• Volume: 402,991 shs
• Average Volume: 288,502 shs
• Market Capitalization: $112.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.50
• Consensus Rating: Hold

Oncocyte Stock Analysis - MarketRank™

Oncocyte scored higher than 29% of companies evaluated by MarketBeat, and ranked 746th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Oncocyte has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Oncocyte has a consensus price target of $10.50, representing about 205.2% upside from its current price of $3.44.

Amount of Analyst Coverage

Oncocyte has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncocyte is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncocyte is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.10% of the float of Oncocyte has been sold short.

Short Interest Ratio / Days to Cover

Oncocyte has a short interest ratio ("days to cover") of 4.76.

Change versus previous month

Short interest in Oncocyte has recently increased by 6.63%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncocyte does not currently pay a dividend.

Dividend Growth

Oncocyte does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 7 news articles for Oncocyte this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oncocyte insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.21% of the stock of Oncocyte is held by insiders.

Percentage Held by Institutions

55.35% of the stock of Oncocyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMDX
• CIK: 1642380
• Web: www.imdxinc.com
• Phone: (949) 409-7600
• Fax: 510-521-3389
• Employees: 58
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Oncocyte: $10.50
• High Price Target: $12.00
• Low Price Target: $9.00
• Potential Upside/Downside: +205.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$50.22 million
• Net Margins: -2,955.63%
• Pretax Margin: -2,955.63%
• Return on Equity: N/A
• Return on Assets: -107.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.00
• Quick Ratio: 1.98

Sales & Book Value

• Annual Sales: $4.05 million
• Price / Sales: 27.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.10) per share
• Price / Book: -3.13

Miscellaneous

• Outstanding Shares: 32,720,000
• Free Float: 32,001,000
• Market Cap: $112.56 million
• Optionable: N/A
• Beta: 1.80